Log In Sign up
The largest database of trusted experimental protocols

Plx8394

Manufactured by Plexxikon
Visit Supplier

PLX8394 is a laboratory equipment product that serves a core function. This concise and unbiased description is provided without any interpretation or extrapolation regarding its intended use.

Automatically generated - may contain errors

Lab products found in correlation

Dabrafenib, by GlaxoSmithKline (3 mentions) Vemurafenib, by Plexxikon (3 mentions) Ly3009120, by Active Motif (3 mentions) Lapatinib, by GlaxoSmithKline (3 mentions) Trametinib, by GlaxoSmithKline (2 mentions) Encorafenib, by Novartis (2 mentions) Hygromycin, by Thermo Fisher Scientific (2 mentions) Tak 632, by Selleck Chemicals (2 mentions) Doxycycline d3072, by Merck Group (2 mentions) 4 hydroxytamoxifen 4 oht h7904, by Merck Group (2 mentions) Dabrafenib, by Selleck Chemicals (1 mentions) Trametinib, by Selleck Chemicals (1 mentions) Birinapant, by Selleck Chemicals (1 mentions) Plx4720, by Plexxikon (1 mentions) Pd0325901, by Selleck Chemicals (1 mentions) Hygromycin stock solution, by Thermo Fisher Scientific (1 mentions) Doxycycline, by Merck Group (1 mentions) Puromycin, by Thermo Fisher Scientific (1 mentions) Plx7904, by Plexxikon (1 mentions) Lgx818, by Novartis (1 mentions)

7 protocols using plx8394

1

Investigating BRAF and MEK Inhibitors

Check if the same lab product or an alternative is used in the 5 most similar protocols
Dabrafenib (BRAF inhibitor), PD0325901 (MEK inhibitor), trametinib (MEK inhibitor), and birinapant were purchased from Selleck Chemicals. PLX4720 (BRAF inhibitor), PLX2695 (MEK inhibitor), and PLX8394 (BRAF inhibitor) were provided by Dr. Gideon Bollag (Plexxikon Inc., Berkeley CA).
Capparelli C., Purwin T.J., Glasheen M., Caksa S., Tiago M., Wilski N., Pomante D., Rosenbaum S., Nguyen M.Q., Cai W., Franco-Barraza J., Zheng R., Kumar G., Chervoneva I., Shimada A., Rebecca V.W., Snook A.E., Hookim K., Xu X., Cukierman E., Herlyn M, & Aplin A.E. (2022). Targeting SOX10-deficient cells to reduce the dormant-invasive phenotype state in melanoma. Nature Communications, 13, 1381.
+ Open protocol
+ Expand
2

Multi-Kinase Inhibitor Screening Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
BGB283 and BGB659 were obtained from Beigene. vemurafenib, PLX7904, PLX8394 from Plexxikon. lapatinib, trametinib, dabrafenib from GlaxoSmithKline. LGX818 is from Novartis. LY3009120 purchased from Active Biochem, Doxycycline from Sigma Aldrich, Puromycin, Hygromycin stock solution from Invitrogene., other drugs from Selleckchem. Drugs were dissolved in DMSO to yield 10mM stock and stored at −20°C.
Yao Z., Torres N.M., Tao A., Gao Y., Luo L., Li Q., de Stanchina E., Abdel-Wahab O., Solit D.B., Poulikakos P, & Rosen N. (2015). BRAF mutants evade ERK dependent feedback by different mechanisms that determine their sensitivity to pharmacologic inhibition. Cancer cell, 28(3), 370-383.
+ Open protocol
+ Expand
3

Comprehensive Drug Treatment Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
BGB659 was obtained from Beigene. Vemurafenib and PLX8394 were from Plexxikon. Lapatinib and dabrafenib were from GlaxoSmithKline. TAK632 was from Selleckchem. encorafenib was from Novartis. LY3009120 was purchased from Active Biochem, All these drugs were dissolved in DMSO to yield 10mM stock and stored at −20 °C Doxycycline (D3072) and 4-hydroxytamoxifen (4-OHT) (H7904) were purchased from Sigma Aldrich, Puromycin (A1113802) and Hygromycin (10687010) stock solution was from Thermo Fisher Scientific.
Yao Z., Gao Y., Su W., Yaeger R., Tao J., Na N., Zhang Y., Zhang C., Rymar A., Tao A., Timaul N.M., Mcgriskin R., Outmezguine N.A., Zhao H., Chang Q., Qeriqi B., Barbacid M., de Stanchina E., Hyman D.M., Bollag G, & Rosen N. (2018). RAF inhibitor PLX8394 selectively disrupts BRAF-dimers and RAS-independent BRAF mutant-driven signaling. Nature medicine, 25(2), 284-291.
+ Open protocol
+ Expand
4

Evaluating Drug Sensitivity in Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
Cells were treated with BETi (2 μM PLX51107 provided by Plexxikon Inc.), CDK4/6i (1 μM PD0332991), etoposide (37.5 μM, Sigma), dacarbazine (20 μM, Sigma), tamoxifen (1 μM, Sigma), ERK1/2i (1 μM SCH772984, SelleckChem), or paradox-breaking BRAFi (500 nM PLX8394 provided by Plexxikon Inc.) for 24 hours. etoposide (37.5 μM) and doxorubicin (1 μM) concentrations were based upon previous publications (59 –61 (link)).
Erkes D.A., Cai W., Sanchez I.M., Purwin T.J., Rogers C., Field C.O., Berger A.C., Hartsough E.J., Rodeck U., Alnemri E.S, & Aplin A.E. (2019). Mutant BRAF and MEK inhibitors regulate the tumor immune microenvironment via pyroptosis. Cancer discovery, 10(2), 254-269.
+ Open protocol
+ Expand
5

Protein Extraction and Western Blotting

Check if the same lab product or an alternative is used in the 5 most similar protocols
Cells were plated at 1x106cells/ml in presence of serum and then serum starved for 24 hours. Cells were exposed to indicated concentrations of drug for 1 hour and then lysed with RIPA lysis buffer (50 mM Tris, 150 mM NaCl, 0.1% SDS, 0.5% sodium deoxycholate, 1% Nonidet P-40, Roche complete protease inhibitor mixture tablets, and 100x Pierce phosphatase inhibitor mixture) while being maintained at 4°C. Cell suspension was centrifuged and clarified lysates isolated. Lysates were protein quantified and diluted to a standard concentration with 2X LDS buffer so all aliquots had the same protein quantification prior to western blotting. Trametinib was provided by GlaxoSmithKline. PLX8394 was provided by Plexxikon. Selumetinib, binimetinib, GDC0623, and cobimetinib were purchased from Selleck Chemicals (Selleckchem.com). Drug studies in soft agar assays were performed as described previously [4 (link)].
Jain P., Silva A., Han H.J., Lang S.S., Zhu Y., Boucher K., Smith T.E., Vakil A., Diviney P., Choudhari N., Raman P., Busch C.M., Delaney T., Yang X., Olow A.K., Mueller S., Haas-Kogan D., Fox E., Storm P.B., Resnick A.C, & Waanders A.J. (2017). Overcoming resistance to single-agent therapy for oncogenic BRAF gene fusions via combinatorial targeting of MAPK and PI3K/mTOR signaling pathways. Oncotarget, 8(49), 84697-84713.
+ Open protocol
+ Expand
6

Evaluating Novel Kinase Inhibitors

Check if the same lab product or an alternative is used in the 5 most similar protocols
PLX7904 (PB04), PLX8394 (PB03) and PLX4720 were provided by Dr. Gideon Bollag (Plexxikon Inc., Berkeley, CA). AZD6244 was purchased from Selleck Chemicals LLC (Houston, TX).
Basile K.J., Le K., Hartsough E.J, & Aplin A.E. (2014). Inhibition of mutant BRAF splice variant signaling by next generation, selective RAF inhibitors. Pigment cell & melanoma research, 27(3), 479-484.
+ Open protocol
+ Expand
7

Comprehensive Drug Treatment Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
BGB659 was obtained from Beigene. Vemurafenib and PLX8394 were from Plexxikon. Lapatinib and dabrafenib were from GlaxoSmithKline. TAK632 was from Selleckchem. encorafenib was from Novartis. LY3009120 was purchased from Active Biochem, All these drugs were dissolved in DMSO to yield 10mM stock and stored at −20 °C Doxycycline (D3072) and 4-hydroxytamoxifen (4-OHT) (H7904) were purchased from Sigma Aldrich, Puromycin (A1113802) and Hygromycin (10687010) stock solution was from Thermo Fisher Scientific.
Yao Z., Gao Y., Su W., Yaeger R., Tao J., Na N., Zhang Y., Zhang C., Rymar A., Tao A., Timaul N.M., Mcgriskin R., Outmezguine N.A., Zhao H., Chang Q., Qeriqi B., Barbacid M., de Stanchina E., Hyman D.M., Bollag G, & Rosen N. (2018). RAF inhibitor PLX8394 selectively disrupts BRAF-dimers and RAS-independent BRAF mutant-driven signaling. Nature medicine, 25(2), 284-291.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!